« Back
Home /
Pevonedistat hydrochloride

Pevonedistat hydrochloride

Item no.	HY-10484-10mg
Manufacturer	MedChem Express
CASRN	1160295-21-5
Amount	10 mg
Quantity options	100 mg 10mM/1mL 10 mg 1 mg 200 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.26
Formula	C21H26ClN5O4S
Citations	Harvard Medical School LINCS LIBRARY<br/>J Pathol. 2021 Feb 27.<br/>Oncotarget. 2017 Oct 12;8(57):97178-97186. <br/>Sci Adv. 2022 Sep 23;8(38):eabq4831.<br/>Am J Physiol Lung Cell Mol Physiol. 2017 Jul 1;313(1):L104-L114.<br/>Am J Physiol Lung Cell Mol Physiol. 2019 Jun 1;316(6):L1070-L1080. <br/>Ann Hematol. 2014 Sep;93(9):1499-508.<br/>Arch Biochem Biophys. 2021 Jul 31;109000.<br/>Arch Biochem Biophys. 2022 May 30;721:109194.<br/>Bioact Mater. 2024 Apr, 34, Pages 366-380.<br/>Biochem Biophys Res Commun. 2017 Jan 29;483(1):223-229. <br/>Biochem Biophys Res Commun. 2018 Nov 17;506(1):108-113. <br/>Biochem Biophys Res Commun. 2019 Sep 3;516(4):1242-1247. <br/>Biochem Biophys Res Commun. 2021 Mar 3;549:150-156.<br/>Biochem Biophys Res Commun. 2019 Jan 15;508(3):986-990. <br/>Biochem Pharmacol. 2024 May:223:116198.<br/>bioRxiv. 2023 Feb 15.<br/>bioRxiv. 2023 Feb 23.<br/>bioRxiv. 2023 Jun 5.<br/>bioRxiv. 2024 Jan 28.<br/>bioRxiv. April.<br/>Biosci Rep. 2022 Jul 26;BSR20220994.<br/>Cancer Cell. 2020 Mar 16;37(3):371-386.e12.<br/>Cancer Chemother Pharmacol. 2018 Jun;81(6):1083-1093.<br/>Cancers. 2019 Jan 15;11(1):97.<br/>Cell Biosci. 2020 Nov 27;10(1):139.<br/>Cell Chem Biol. 2021 Jul 15;S2451-9456(21)00312-3.<br/>Cell Cycle. 2019 Sep;18(18):2307-2322.<br/>Cell Death Differ. 2020 Apr;27(4):1383-1397. <br/>Cell Death Differ. 2021 Jul 2.<br/>Cell Death Discov. 2022 Jul 12;8(1):316.<br/>Cell Death Discov. 2022 May 2;8(1):238.<br/>Cell Metab. 2023 Jul 28;S1550-4131(23)00263-2.<br/>Cell Rep. 2021 Aug 24;36(8):109568.<br/>Cell Rep. 2021 Jul 20;36(3):109394.<br/>Cell Rep. 2024 Feb 27;43(2):113749.<br/>Cell Res. 2021 Mar;31(3):291-311.<br/>Cell. 2019 Jul 11;178(2):330-345.e22.<br/>Cell. 2023 Apr 27;186(9):1895-1911.e21.<br/>Cells. 2020 Mar 30;9(4):834.<br/>Cells. 2021, 10(11), 2803.<br/>Clin Transl Med. 2020 Jun;10(2):e113.<br/>Commun Biol. 2021 Sep 13;4(1):1066.<br/>Comput Struct Biotechnol J. 1 October 2021.<br/>Dev Cell. 2019 Feb 11;48(3):329-344.e5.<br/>Elife. 2016 Apr 11;5:e14087.<br/>Elife. 2018 Aug 1;7:e38430. <br/>Elife. 2020 Jun 2;9:e54954.<br/>Elife. 2019 Mar 25;8:e45457. <br/>EMBO J. 2019 Dec 2;38(23):e101409.<br/>Eur J Med Chem. 2023 Aug 19, 115732.<br/>Eur Rev Med Pharmacol Sci. 2018 Dec;22(23):8273-8280.<br/>Exp Cell Res. 2020 Jul 15;392(2):112038.<br/>FASEB J. 2021 Aug;35(8):e21800.<br/>Front Cell Dev Biol. 2021 Apr 30.<br/>Front Cell Dev Biol. 2021 Apr 30;9:667435.<br/>Front Immunol. 2022 Jul 4;13:925702.<br/>Front Oncol. 2017 Dec 11;7:293.<br/>Front Oncol. 2022 Jan 26;12:822039.<br/>Harvard University. 2023 Mar. 30487357.<br/>Institut für Pharmazeutische Wissenschaften. 2020 Nov.<br/>Institute of Molecular Virology. Ulm University. 2017 Jan.<br/>Int J Med Sci. 2018 Apr 3;15(7):674-681.<br/>Int J Mol Sci. 2023, 24(4), 3415.<br/>iScience. 2023 Mar.<br/>J Biol Chem. 15 October 2021, 101307.<br/>J Biol Chem. 2022 Sep 12;102484.<br/>J Cell Physiol. 2022 May 16.<br/>J Exp Med. 2018 Aug 6;215(8):1999-2017. <br/>J Immunol. 2021 Jun 28;ji2001167.<br/>J Med Chem. 2021 Dec 29.<br/>J Med Chem. 2021 Jun 17.<br/>J Med Chem. 2023 Jun 30.<br/>J Med Chem. 2023 Mar 9.<br/>J Med Chem. 2023 Sep 6.<br/>J Virol. 2022 May 25;96(10):e0059822.<br/>J Virol. 2024 Feb 20;98(2):e0190923.<br/>Lab Invest. 2019 Apr;99(4):528-538.<br/>Mbio. 2020 Jul 14;11(4):e00782-20.<br/>Mol Cancer Res. 2023 Feb 8;MCR-22-0648.<br/>Mol Cell. 2022 Feb 17;S1097-2765(22)00085-5.<br/>Mol Cell. 2023 Nov 16:S1097-2765(23)00913-9.<br/>Mol Metab. 2021 Jun 18;101275.<br/>Mol Ther Oncolytics. 2020 Jun 23;18:215-225.<br/>Nat Chem Biol. 2023 Aug 31.<br/>Nat Chem Biol. 2023 Sep 7.<br/>Nat Chem Biol. 2024 Mar 21.<br/>Nat Commun. 2017 May 22;8:15398. <br/>Nat Commun. 2018 Sep 18;9(1):3801. <br/>Nat Commun. 2021 Sep 10;12(1):5386.<br/>Nat Commun. 2022 Oct 10;13(1):5973.<br/>Nat Commun. 2022 Sep 2;13(1):5173.<br/>Nat Commun. 2024 Jan 11;15(1):468.<br/>Nat Microbiol. 2019 May;4(5):813-825.<br/>Nat Plants. 2019 Jan;5(1):34-40. <br/>Nat Struct Mol Biol. 2024 Jan 4.<br/>Nature Cancer. 2021 Apr;2(4):429-443.<br/>Nature. 2020 Dec;588(7836):164-168.<br/>Neoplasia. 2022 Jul 27;32:100823.<br/>Neurobiol Dis. 2020 Sep;143:105013.<br/>Oncol Lett. 2019 Sep;18(3):2724-2732. <br/>Oncotarget. 2016 Jun 14;7(24):35643-35654.<br/>Oncotarget. 2016 Oct 4;7(40):66087-66099.<br/>Oncotarget. 2017 Sep 23;8(49):86395-86409. <br/>Patent. US20180263995A1.<br/>Patent. US20220175722A1.<br/>Patent. US20220280649A1.<br/>Patent. US20220281931A1.<br/>Patent. US20220378919A1.<br/>Pharmaceuticals. 2024 May 11.<br/>Proc Natl Acad Sci U S A. 2022 Feb 8;119(6):e2111737119.<br/>Protein Sci. 2021 Aug 30.<br/>Redox Biol. 2021 Aug 24;46:102114.<br/>Research Square Preprint. 2021 Jun.<br/>Research Square Preprint. 2022 Jul.<br/>Research Square Print. 2022.<br/>Sci Adv. 2024 Apr 12;10(15):eadm7600.<br/>Signal Transduct Target Ther. 2024 Jan 15;9(1):18.<br/>Technol Cancer Res Treat. 2016 Aug;15(4):527-34. <br/>Virology. 2015 Mar;477:10-7. <br/>Viruses. 2023 Nov 30, 15(12), 2356.<br/>[1]Soucy TA, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009 Apr 9;458(7239):732-6.<br/>[2]J. Claire Godbersen, e tal. The Nedd8-Activating Enzyme Inhibitor MLN4924 Thwarts Microenvironment-Driven NF-κB Activation and Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells.<br/>[3]Lan H, et al. Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells. Sci Rep. 2016 Apr 11;6:24218.
Smiles	O=S(OC[C@H]1[C@H](C[C@@H](C1)N2C=CC3=C(N=CN=C32)N[C@H]4CCC5=C4C=CC=C5)O)(N)=O.Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	MLN4924 (hydrochloride)
Available
Product Description	Pevonedistat hydrochloride (MLN4924 hydrochloride) is a potent and selective NEDD8-activating enzyme (NAE) inhibitor, with an IC50 of 4.7 nM[1].
StorageTemperature	4°C (Powder, sealed storage, away from moisture)
Shipping	Room Temperature
Manufacturers Applications	Cancer-programmed cell death
MolecularWeight	479.98
Clinical Information	Phase 3
Manufacturers Research Area	Cancer
Solubility	DMSO : 100 mg/mL (ultrasonic)\|H2O : 10 mg/mL (ultrasonic)
Target	NEDD8-activating Enzyme
Manufacturers Target	NEDD8-activating Enzyme
Manufacturers Pathway	Metabolic Enzyme/Protease
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-10484-10mg-safety-datasheet.pdf